P2.02-018 Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients

Abstract

selected due to their paired nature, complete with both LUAD and nonmalignant lung profiles (TCGA n¼108, BCCA n¼72). LncRNAs were filtered based on positional overlap within pseudogene loci, and a Wilcoxon sign-rank test was run to identify lncRNAs with significantly altered expression between paired tumor and normal tissues (FDR p<0.05). To identify lncRNAs that likely regulate protein-coding parent gene expression in trans, tumors were ranked by lncRNA expression, and protein-coding parent gene expression of top and bottom ranked tertiles was compared by Mann Whitney U-test (p<0.05). Survival analysis was performed using a Cox proportional hazard model. Result: Our analysis has identified 129 lncRNAs expressed from pseudogene loci that were significantly deregulated in LUAD in both datasets. Remarkably, many of these deregulated lncRNAs (i) were expressed from the loci of pseudogenes related to known cancer genes, (ii) had expression that significantly correlated with protein-coding parent gene expression, and (iii) protein-coding parent gene expression was significantly associated with survival. For example, RP11-182J1.1 is a lncRNA expressed from a pseudogene to EGLN1, a previously described cancer gene involved in regulation of tumor hypoxia. RP11-182J1.1 was underexpressed in LUAD and significantly positively correlated with EGLN1 expression. In addition, EGLN1 was significantly associated with patient survival (p¼1.2e-08) emphasizing the clinical potential of these lncRNAs. Conclusion: This work uncovers evidence to suggest the lncRNA-pseudogene-protein-coding gene axis is a prominent mechanism of cancer gene regulation. Further characterization of this understudied gene regulatory mechanism could lead to novel therapies that silence oncogenes or reactivate tumor suppressor genes.

Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report

“…Epidermal growth factor receptor (EGFR) is one of the most important oncogenes in non-small cell lung cancer (NSCLC) (1). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been shown to prolong the survival of patients with EGFR mutations, but acquired resistance often develops within 10-14 months (2).…”